Pixabay/HeungSoon
12 October 2021
New research published in British Journal of Ophthalmology has highlighted that a common class of diabetes medication may lower an individual’s risk of developing glaucoma by half.
Scientists from the University of Pennsylvania examined data relating to 1961 diabetic patients who had recently started taking GLP-1R agonists. They compared this information to the records of 4371 diabetic patients who were not taking this class of medication.
After 150 days, 0.5% of patients taking the medication had developed glaucoma, compared to 1.3% of patients developing the eye disease in the control group.
The authors highlighted: “Our findings support further investigations into the use of GLP-1R agonists in glaucoma prevention.”
The research is supported by another study in 2020 which revealed that this type of medication reduced neuroinflammation and prevented retinal ganglion cell death in mice.
Scientists from the University of Pennsylvania examined data relating to 1961 diabetic patients who had recently started taking GLP-1R agonists. They compared this information to the records of 4371 diabetic patients who were not taking this class of medication.
After 150 days, 0.5% of patients taking the medication had developed glaucoma, compared to 1.3% of patients developing the eye disease in the control group.
The authors highlighted: “Our findings support further investigations into the use of GLP-1R agonists in glaucoma prevention.”
The research is supported by another study in 2020 which revealed that this type of medication reduced neuroinflammation and prevented retinal ganglion cell death in mice.
Comments (0)
You must be logged in to join the discussion. Log in